214 related articles for article (PubMed ID: 15182192)
1. Interaction model for anthracycline activity against DNA topoisomerase II.
Moro S; Beretta GL; Dal Ben D; Nitiss J; Palumbo M; Capranico G
Biochemistry; 2004 Jun; 43(23):7503-13. PubMed ID: 15182192
[TBL] [Abstract][Full Text] [Related]
2. DNA topoisomerase II structures and anthracycline activity: insights into ternary complex formation.
Dal Ben D; Palumbo M; Zagotto G; Capranico G; Moro S
Curr Pharm Des; 2007; 13(27):2766-80. PubMed ID: 17897022
[TBL] [Abstract][Full Text] [Related]
3. DNA topoisomerase II as the primary target of anti-tumor anthracyclines.
Zunino F; Capranico G
Anticancer Drug Des; 1990 Nov; 5(4):307-17. PubMed ID: 1963303
[TBL] [Abstract][Full Text] [Related]
4. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.
De Isabella P; Capranico G; Palumbo M; Sissi C; Krapcho AP; Zunino F
Mol Pharmacol; 1993 May; 43(5):715-21. PubMed ID: 8388987
[TBL] [Abstract][Full Text] [Related]
5. In vivo site specificity and human isoenzyme selectivity of two topoisomerase II-poisoning anthracyclines.
Binaschi M; Farinosi R; Borgnetto ME; Capranico G
Cancer Res; 2000 Jul; 60(14):3770-6. PubMed ID: 10919649
[TBL] [Abstract][Full Text] [Related]
6. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
Gupta M; Abdel-Megeed M; Hoki Y; Kohlhagen G; Paull K; Pommier Y
Mol Pharmacol; 1995 Oct; 48(4):658-65. PubMed ID: 7476891
[TBL] [Abstract][Full Text] [Related]
7. Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide.
Liu YX; Hsiung Y; Jannatipour M; Yeh Y; Nitiss JL
Cancer Res; 1994 Jun; 54(11):2943-51. PubMed ID: 8187080
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of the topoisomerase II poison 9-amino-[N-(2-dimethylamino)ethyl]acridine-4-carboxamide bound to the DNA hexanucleotide d(CGTACG)2.
Adams A; Guss JM; Collyer CA; Denny WA; Wakelin LP
Biochemistry; 1999 Jul; 38(29):9221-33. PubMed ID: 10413496
[TBL] [Abstract][Full Text] [Related]
9. Position-specific trapping of topoisomerase II by benzo[a]pyrene diol epoxide adducts: implications for interactions with intercalating anticancer agents.
Khan QA; Kohlhagen G; Marshall R; Austin CA; Kalena GP; Kroth H; Sayer JM; Jerina DM; Pommier Y
Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12498-503. PubMed ID: 14523238
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of topoisomerase II-mediated DNA cleavage by three DNA-intercalating plant alkaloids: cryptolepine, matadine, and serpentine.
Dassonneville L; Bonjean K; De Pauw-Gillet MC; Colson P; Houssier C; Quetin-Leclercq J; Angenot L; Bailly C
Biochemistry; 1999 Jun; 38(24):7719-26. PubMed ID: 10387011
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.
Wu CC; Li TK; Farh L; Lin LY; Lin TS; Yu YJ; Yen TJ; Chiang CW; Chan NL
Science; 2011 Jul; 333(6041):459-62. PubMed ID: 21778401
[TBL] [Abstract][Full Text] [Related]
12. Change of the sequence specificity of daunorubicin-stimulated topoisomerase II DNA cleavage by epimerization of the amino group of the sugar moiety.
Capranico G; Butelli E; Zunino F
Cancer Res; 1995 Jan; 55(2):312-7. PubMed ID: 7812964
[TBL] [Abstract][Full Text] [Related]
13. Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage.
Capranico G; Palumbo M; Tinelli S; Mabilia M; Pozzan A; Zunino F
J Mol Biol; 1994 Jan; 235(4):1218-30. PubMed ID: 8308885
[TBL] [Abstract][Full Text] [Related]
14. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
[TBL] [Abstract][Full Text] [Related]
15. Structural homology between DNA binding sites of DNA polymerase beta and DNA topoisomerase II.
Mizushina Y; Sugawara F; Iida A; Sakaguchi K
J Mol Biol; 2000 Dec; 304(3):385-95. PubMed ID: 11090281
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
Animati F; Arcamone F; Bigioni M; Capranico G; Caserini C; De Cesare M; Lombardi P; Pratesi G; Salvatore C; Supino R; Zunino F
Mol Pharmacol; 1996 Sep; 50(3):603-9. PubMed ID: 8794900
[TBL] [Abstract][Full Text] [Related]
17. Random mutagenesis of the B'A' core domain of yeast DNA topoisomerase II and large-scale screens of mutants resistant to the anticancer drug etoposide.
Jiang X
Biochem Biophys Res Commun; 2005 Feb; 327(2):597-603. PubMed ID: 15629155
[TBL] [Abstract][Full Text] [Related]
18. A computational model for anthracycline binding to DNA: tuning groove-binding intercalators for specific sequences.
Cashman DJ; Kellogg GE
J Med Chem; 2004 Mar; 47(6):1360-74. PubMed ID: 14998326
[TBL] [Abstract][Full Text] [Related]
19. Interactions between morpholinyl anthracyclines and DNA. The crystal structure of a morpholino doxorubicin bound to d(CGTACG).
Cirilli M; Bachechi F; Ughetto G; Colonna FP; Capobianco ML
J Mol Biol; 1993 Apr; 230(3):878-89. PubMed ID: 8478940
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase II antagonism and anticancer activity of coordinated derivatives of [RuCl(2)(C(6)H(6))(dmso)].
Vashisht Gopal YN; Konuru N; Kondapi AK
Arch Biochem Biophys; 2002 May; 401(1):53-62. PubMed ID: 12054487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
